(e.g., crizotinib, ceritinib, brigantinib, alectinib, lorlatinib)
before cancer treatment begins
Cardio-oncological evaluation* AND Home blood pressure monitoring for brigatinib and lorlatinib
every 3 months for 1 year, then every 6 months during cancer treatment
* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.